The global cervical cancer diagnostic market size was estimated to be USD 4.84 billion in 2023 and is expected to reach at USD 9.03 billion by 2034 with a CAGR of 5.83% during the forecast period 2024-2034. Growing prevalence of cervical cancer, rising screening & diagnostic tests, increasing demand for the early detection of disease, surge in government initiatives for the detection & treatment of cervical cancer, growing awareness regarding the disease, the existence of favorable reimbursement policies, rising technological advancements in new diagnostic equipment & diagnostic procedures, increasing research & development activities, and surge in regulatory approval of cervical cancer diagnostic tests are some of the key factors boosting the market growth.
Surge in regulatory approval of cervical cancer diagnostic tests is predicted to boost the market growth during the forecast period. Cervical cancer originates in the cervix of the uterus in women, where abnormal cells begin to proliferate, potentially progressing into cancerous cells. Diagnostic tests for cervical cancer are designed to identify precancerous alterations in cells and tissues, enabling early detection for more effective treatment. Timely detection significantly improves the chances of successful treatment for cervical cancer. Even in advanced stages, it can be managed with appropriate medical intervention. Consequently, industry stakeholders are prioritizing the development of novel diagnostic tests for this purpose. For instance, in February 2023, BD and Company (Becton, Dickinson and Company) has announced that the BD Onclarity HPV Assay has received approval from the U.S. Food and Drug Administration (FDA) for its combined use with the ThinPrep Pap Test.
By test type, pap testing was the highest revenue-grossing segment in the global cervical cancer diagnostic market in 2023 owing to its convenience, rising adoption of Pap Smear Tests for diagnosis of the cervical cancer, and growing launch of advanced tests. Additionally, HPV testing is predicted to grow at fastest CAGR during the forecast period owing to the growing number of patients with HPV, the existence of human papillomavirus (HPV) infection and the accessibility of at-home sample collection kits for HPV testing. For instance, in June 2022, Roche has launched an HPV self-sampling solution in regions acknowledging the CE mark. This novel approach enables patients to autonomously gather their HPV screening sample in a confidential environment within a healthcare facility, under the guidance of a healthcare expert. The collected vaginal sample, which has been clinically validated, is subsequently subjected to analysis using the Roche cobas HPV test on a Roche molecular instrument.
By age group, 20-40 years was the highest revenue-grossing segment in the global cervical cancer diagnostic market in 2023 owing to a significant portion of sexually active women falls within this age range, lifestyle factors such as alcohol consumption, smoking, & obesity are more commonly observed among women in this particular age group, and increasing launch of test kits. For instance, in January 2023, Virax Biolabs, an innovative biotechnology company focused on viral disease prevention, detection, and diagnosis, has announced its intention to supply HPV test kits. The delivery of these kits is anticipated to begin in the initial quarter of 2023, with a focus on markets that acknowledge the CE mark, such as the European Union. Additionally, above 40 years is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of patients visiting the hospitals for diagnosis of the cervical cancer and surge in government support for diagnosis of cervical cancer.
By end-user, diagnostic centers was the highest revenue-grossing segment in the global cervical cancer diagnostic market in 2023 owing to the presence of numerous service choices & diagnostic devices in healthcare & diagnostic centers, increasing preference among patients for diagnostic centers over hospitals or labs for their diagnostic needs and surge in launch of new test. For instance, in June 2022, Karkinos Healthcare, a health technology platform specializing in oncology, has unveiled CerviRaksha, a groundbreaking HPV test that has undergone clinical validation. This test holds prequalification from the World Health Organization and has been granted approval by the U.S. Food and Drug Administration. Notably, it was developed in partnership with medical professionals from the Karkinos network hospitals, including doctors and nurses. Additionally, diagnostic center is predicted to grow at fastest CAGR during the forecast period owing to the increasing emphasis on preventive measures, rising demand for diagnostic testing, and surge in adoption of home diagnostics due to the convenience they offer for testing at home.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in number of patients suffering from cervical cancer, increasing adoption of cervical cancer detection techniques, growing expenditure on research & development activities, and increasing emphasis on developing novel tests. For instance, in June 2023, As reported by LabMedica, Rice University bioengineers have created an affordable, point-of-care DNA test for detecting HPV infections. This test has the potential to enhance the accessibility of cervical cancer screening, particularly in low- and middle-income countries where the disease claims the lives of over 300,000 women annually. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising occurrence of cervical cancer, expanding healthcare infrastructure, increasing research and development activities, and growing regulatory approvals. For instance, in January 2022, SANSURE BIOTECH INC., a provider of in-vitro diagnostic products, has revealed that its 'HPV DNA Diagnostic Kit (HPV 13+2)' has received approval from the China National Medical Products Administration (NMPA). This kit is designed using advanced magnetic beads technology and encompasses over 13 high-risk genotypes to ensure its effectiveness in cervical cancer screening.
Surge in regulatory approval of cervical cancer diagnostic tests is predicted to boost the market growth during the forecast period. Cervical cancer originates in the cervix of the uterus in women, where abnormal cells begin to proliferate, potentially progressing into cancerous cells. Diagnostic tests for cervical cancer are designed to identify precancerous alterations in cells and tissues, enabling early detection for more effective treatment. Timely detection significantly improves the chances of successful treatment for cervical cancer. Even in advanced stages, it can be managed with appropriate medical intervention. Consequently, industry stakeholders are prioritizing the development of novel diagnostic tests for this purpose. For instance, in February 2023, BD and Company (Becton, Dickinson and Company) has announced that the BD Onclarity HPV Assay has received approval from the U.S. Food and Drug Administration (FDA) for its combined use with the ThinPrep Pap Test.
By test type, pap testing was the highest revenue-grossing segment in the global cervical cancer diagnostic market in 2023 owing to its convenience, rising adoption of Pap Smear Tests for diagnosis of the cervical cancer, and growing launch of advanced tests. Additionally, HPV testing is predicted to grow at fastest CAGR during the forecast period owing to the growing number of patients with HPV, the existence of human papillomavirus (HPV) infection and the accessibility of at-home sample collection kits for HPV testing. For instance, in June 2022, Roche has launched an HPV self-sampling solution in regions acknowledging the CE mark. This novel approach enables patients to autonomously gather their HPV screening sample in a confidential environment within a healthcare facility, under the guidance of a healthcare expert. The collected vaginal sample, which has been clinically validated, is subsequently subjected to analysis using the Roche cobas HPV test on a Roche molecular instrument.
By age group, 20-40 years was the highest revenue-grossing segment in the global cervical cancer diagnostic market in 2023 owing to a significant portion of sexually active women falls within this age range, lifestyle factors such as alcohol consumption, smoking, & obesity are more commonly observed among women in this particular age group, and increasing launch of test kits. For instance, in January 2023, Virax Biolabs, an innovative biotechnology company focused on viral disease prevention, detection, and diagnosis, has announced its intention to supply HPV test kits. The delivery of these kits is anticipated to begin in the initial quarter of 2023, with a focus on markets that acknowledge the CE mark, such as the European Union. Additionally, above 40 years is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of patients visiting the hospitals for diagnosis of the cervical cancer and surge in government support for diagnosis of cervical cancer.
By end-user, diagnostic centers was the highest revenue-grossing segment in the global cervical cancer diagnostic market in 2023 owing to the presence of numerous service choices & diagnostic devices in healthcare & diagnostic centers, increasing preference among patients for diagnostic centers over hospitals or labs for their diagnostic needs and surge in launch of new test. For instance, in June 2022, Karkinos Healthcare, a health technology platform specializing in oncology, has unveiled CerviRaksha, a groundbreaking HPV test that has undergone clinical validation. This test holds prequalification from the World Health Organization and has been granted approval by the U.S. Food and Drug Administration. Notably, it was developed in partnership with medical professionals from the Karkinos network hospitals, including doctors and nurses. Additionally, diagnostic center is predicted to grow at fastest CAGR during the forecast period owing to the increasing emphasis on preventive measures, rising demand for diagnostic testing, and surge in adoption of home diagnostics due to the convenience they offer for testing at home.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in number of patients suffering from cervical cancer, increasing adoption of cervical cancer detection techniques, growing expenditure on research & development activities, and increasing emphasis on developing novel tests. For instance, in June 2023, As reported by LabMedica, Rice University bioengineers have created an affordable, point-of-care DNA test for detecting HPV infections. This test has the potential to enhance the accessibility of cervical cancer screening, particularly in low- and middle-income countries where the disease claims the lives of over 300,000 women annually. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising occurrence of cervical cancer, expanding healthcare infrastructure, increasing research and development activities, and growing regulatory approvals. For instance, in January 2022, SANSURE BIOTECH INC., a provider of in-vitro diagnostic products, has revealed that its 'HPV DNA Diagnostic Kit (HPV 13+2)' has received approval from the China National Medical Products Administration (NMPA). This kit is designed using advanced magnetic beads technology and encompasses over 13 high-risk genotypes to ensure its effectiveness in cervical cancer screening.
Segmentation: Cervical Cancer Diagnostic Market Report 2023 - 2034
Cervical Cancer Diagnostic Market Analysis & Forecast by Test Type 2023 - 2034 (Revenue USD Bn)
- Cervical Biopsies
- Pap Testing
- Colposcopy
- Cystoscopy
- HPV Testing
- Others
Cervical Cancer Diagnostic Market Analysis & Forecast by Age Group 2023 - 2034 (Revenue USD Bn)
- 20-40 Years
- Above 40 Years
Cervical Cancer Diagnostic Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Laboratories
- Hospitals
- Diagnostic Centers
Cervical Cancer Diagnostic Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cervical Cancer Diagnostic Market: Test Type Estimates & Trend Analysis
8. Cervical Cancer Diagnostic Market: Age Group Estimates & Trend Analysis
9. Cervical Cancer Diagnostic Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Cervical Cancer Diagnostic Market
12. Europe Global Cervical Cancer Diagnostic Market
13. Asia Pacific Global Cervical Cancer Diagnostic Market
14. Latin America Global Cervical Cancer Diagnostic Market
15. MEA Global Cervical Cancer Diagnostic Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc
- Beckton
- Dickinson and Company
- Quigan NV
- Siemens Healthineers
- CooperSurgical Inc
- Roche
- Abbott Laboratories
- Karkinos Healthcare
- Carl Zeiss AG
- Hologic Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 4.84 Billion |
| Forecasted Market Value ( USD | $ 9.03 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
